107 RAGE Blockade Inhibits Surgery-Induced Cerebral Edema Following Glioma Resection

View at publisher Summarise with VIRAT
Authors: Mojtaba Dayyani, Aleksandr Filippov, Ian Zhang, Joseph Georges, Zaan Saeed, Jillyn R Turunen, Nick Sobhanian, Huiling Yuan, Lu Zhang, Massimo D’Apuzzo, Jana Portnow, Behnam Badie
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Cerebral edema (CE) often contributes to functional deterioration following brain tumor surgery. Although corticosteroids can alleviate CE during the perioperative period, they impose several undesirable side effects and interfere with immunotherapies in patients with malignant brain tumors. METHODS: Mice harboring orthotopic CT-2A gliomas were randomly assigned to four treatment groups prior to tumor resection by fluorescence-guided microsurgery. TTP488, FPS-ZM1, dexamathasone, and vehicle were administered perioperatively (day 4 pre-op to day 7 post-op), and post-operative CE and neurological function were examined. CE was assessed on serial brain MRIs over a 7-day period and quantified using manual segmentation techniques. The effect of each RAGE inhibitor on anti-PD-1 immunotherapy response and wound healing was also examined. RESULTS: In each group (n=10), CE peaked on post-operative day 2 and gradually diminished by day 7. On post-operative day one, mice treated with TTP488 and FPS-ZM1 showed marked reduction in CE compared to those treated with either dexamethasone or vehicle (P=0.005, TTP488 vs vehicle; P= 0.02, FPS-ZM1 vs vehicle). Furthermore, unlike dexamethasone, neither RAGE inhibitor abrogated the efficacy of immunotherapy in the syngeneic glioma models. Interestingly, the FPS-ZM1 group had better functional recovery scores and wound healing than the vehicle group. CONCLUSIONS: RAGE inhibitors were as effective as dexamethasone in alleviating post-operative CE and, unlike dexamethasone, did not interfere with the efficacy of immunotherapy or wound healing. Thus, RAGE inhibitors could be alternatives to dexamethasone in the perioperative management of CE in patients with brain tumors who are concurrently receiving immunotherapies.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Advanced Glycation End Products research Cancer Stress Anesthesia and Immune Response

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
13–13
Publication date
26 March 2026
Language
EN